- Home
- CSTL
as 05-16-2025 4:00pm EST
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FRIENDSWOOD |
| Market Cap: | 558.7M | IPO Year: | 2019 |
| Target Price: | $38.33 | AVG Volume (30 days): | 548.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.70 - $35.84 | Next Earning Date: | 05-05-2025 |
| Revenue: | $347,083,000 | Revenue Growth: | 38.43% |
| Revenue Growth (this year): | -9.95% | Revenue Growth (next year): | 1.80% |
Stock Insider Trading Activity of Castle Biosciences Inc. (CSTL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Mar 26 '25 | Sell | $20.30 | 5,644 | $114,573.20 | 4,605 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Mar 7 '25 | Sell | $20.34 | 29,177 | $585,673.31 | 4,605 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Mar 4 '25 | Sell | $20.86 | 5,687 | $118,619.45 | 4,605 | |
| Stokes Frank | CSTL | Chief Financial Officer | Feb 20 '25 | Sell | $26.70 | 8,046 | $214,828.20 | 35,319 |
Latest Castle Biosciences Inc. News
CSTL Breaking Stock News: Dive into CSTL Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
Simply Wall St.
12 days ago
Castle Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
GlobeNewswire
12 days ago
Castle Biosciences Celebrates Skin Cancer Awareness Month
Thomson Reuters StreetEvents
13 days ago
Q1 2025 Castle Biosciences Inc Earnings Call
GuruFocus.com
13 days ago
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Zacks
13 days ago
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
13 days ago
Castle Biosciences Reports First Quarter 2025 Results
GlobeNewswire
13 days ago
Castle Biosciences to Acquire Previse
Compare CSTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CSTL Castle Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.